Literature DB >> 23754822

Safety of surgery after rituximab therapy in 133 patients with rheumatoid arthritis: data from the autoimmunity and rituximab registry.

S Godot, J-E Gottenberg, S Paternotte, I Pane, B Combe, J Sibilia, R-M Flipo, T Schaeverbeke, P Ravaud, E Toussirot, F Berenbaum, X Mariette, D Wendling, J Sellam.   

Abstract

OBJECTIVE: We used data from the AutoImmunity and Rituximab (AIR) registry to investigate the safety of surgery for patients with rheumatoid arthritis receiving rituximab (RTX) in routine care.
METHODS: Data for patients included in the AIR registry and undergoing surgery during the year following an infusion of RTX were reviewed to describe the frequency of postsurgical complications, compare patients with and without complications, and identify factors associated with complications.
RESULTS: We examined data for 133 patients with a known date of surgery and at least 1 followup visit, corresponding to 140 procedures, including 94 orthopedic surgeries (67%) and 23 abdominal surgeries (16.5%). The median delay between surgery and the last RTX infusion was 6.4 months (interquartile range 4.3– 8.7 months), without any difference between patients with and without complications. Nine patients (6.7%) experienced 12 complications (8.5%), including 8 surgical site infections (5.7%) and 1 death due to septic shock. Postoperative complications occurred after 4.3% of abdominal surgeries (1 of 23) and 7.4% of orthopedic surgeries (7 of 95). On univariate analysis, spine surgery was associated with postoperative complications (P = 0.048).
CONCLUSION: In common practice, the risk of complications may be more important in case of spine surgery, but does not seem to be linked to the time between the last RTX infusion and surgery.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23754822     DOI: 10.1002/acr.22056

Source DB:  PubMed          Journal:  Arthritis Care Res (Hoboken)        ISSN: 2151-464X            Impact factor:   4.794


  9 in total

Review 1.  A comprehensive review of rituximab therapy in rheumatoid arthritis patients.

Authors:  Soheil Tavakolpour; Samira Alesaeidi; Mohammad Darvishi; Mojtaba GhasemiAdl; Sahar Darabi-Monadi; Meisam Akhlaghdoust; Somayeh Elikaei Behjati; Arash Jafarieh
Journal:  Clin Rheumatol       Date:  2019-08-01       Impact factor: 2.980

Review 2.  Perioperative management of immunosuppression in patients with rheumatoid arthritis.

Authors:  Michael D George; Joshua F Baker
Journal:  Curr Opin Rheumatol       Date:  2019-05       Impact factor: 5.006

Review 3.  Optimizing Rheumatoid Arthritis Patients for Surgery.

Authors:  Alana Sigmund; Linda A Russell
Journal:  Curr Rheumatol Rep       Date:  2018-06-25       Impact factor: 4.592

Review 4.  Prevention of Infection in the Perioperative Setting in Patients with Rheumatic Disease Treated with Immunosuppression.

Authors:  Joshua F Baker; Michael D George
Journal:  Curr Rheumatol Rep       Date:  2019-03-08       Impact factor: 4.592

Review 5.  Optimizing perioperative outcomes for older patients with rheumatoid arthritis undergoing arthroplasty: emphasis on medication management.

Authors:  Susan M Goodman
Journal:  Drugs Aging       Date:  2015-05       Impact factor: 3.923

Review 6.  Perioperative management of the patient with rheumatoid arthritis.

Authors:  Megan L Krause; Eric L Matteson
Journal:  World J Orthop       Date:  2014-07-18

Review 7.  Preoperative Evaluation and Management of Patients Receiving Biologic Therapies.

Authors:  Zahra Rezaieyazdi; Maryam Sahebari; Mandana Khodashahi
Journal:  Arch Bone Jt Surg       Date:  2019-05

8.  Rheumatoid Arthritis in Spine Surgery: A Systematic Review and Meta-Analysis.

Authors:  Benjamin D Streufert; Chiduziem Onyedimma; Yagiz U Yolcu; Abdul Karim Ghaith; Benjamin D Elder; Ahmad Nassr; Bradford Currier; Arjun S Sebastian; Mohamad Bydon
Journal:  Global Spine J       Date:  2022-03-18

9.  EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update.

Authors:  Josef S Smolen; Robert Landewé; Ferdinand C Breedveld; Maya Buch; Gerd Burmester; Maxime Dougados; Paul Emery; Cécile Gaujoux-Viala; Laure Gossec; Jackie Nam; Sofia Ramiro; Kevin Winthrop; Maarten de Wit; Daniel Aletaha; Neil Betteridge; Johannes W J Bijlsma; Maarten Boers; Frank Buttgereit; Bernard Combe; Maurizio Cutolo; Nemanja Damjanov; Johanna M W Hazes; Marios Kouloumas; Tore K Kvien; Xavier Mariette; Karel Pavelka; Piet L C M van Riel; Andrea Rubbert-Roth; Marieke Scholte-Voshaar; David L Scott; Tuulikki Sokka-Isler; John B Wong; Désirée van der Heijde
Journal:  Ann Rheum Dis       Date:  2013-10-25       Impact factor: 19.103

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.